• Home
• About us
• Contact

• News
• People
• Products
• Deals
• Organisations

• Twitter
• Newsletter

Advertisement

Product › Details

cancer drug

	Next higher product group	pharmaceutical
	Status	1998-01-01 sales existent

Record changed: 2022-07-12

Advertisement

More documents for cancer drug

• [1] BioNTech SE. (8/5/22). "Press Release: BioNTech and Genmab Expand Global Strategic Collaboration to Develop and Commercialize Novel Immunotherapy Candidates". Mainz & Copenhagen....
• [2] Active Biotech AB. (8/4/22). "Press Release: Active Biotech Announces a Rights Issue of approximately SEK 55 Million [Not for release in US, AU, CA, JP, et al.]"....
• [3] Heidelberg Pharma AG. (7/13/22). "Press Release: Heidelberg Pharma and Chiome Bioscience Sign Exclusive, Target-Specific Research and Option Agreement for the Development of an Antibody Drug Conjugate (ad hoc)". Ladenburg....
• [4] BioInvent International AB. (7/12/22). "Press Release: BioInvent Has Successfully Carried Out a Directed Share Issue of approximately SEK 300 Million (approximately USD 28.3 Million) [ Not for US, AU, et al. ]". Lund....
• [5] ADC Therapeutics S.A.. (7/8/22). "Press Release: ADC Therapeutics Announces Exclusive License Agreement with Sobi to Develop and Commercialize Zynlonta (loncastuximab tesirine-lpyl) in Europe and Select International Territories". Lausanne....
• [6] Ryvu Therapeutics S.A.. (7/7/22). "Press Release: Exelixis and Ryvu Therapeutics Establish Exclusive License Agreement to Develop Novel STING Agonist-Based Targeted Cancer Therapies". Alameda, CA & Krakow....
• [7] ADC Therapeutics S.A.. (7/1/22). "Press Release: ADC Therapeutics Appoints Jean-Pierre Bizzari, MD, to Board of Directors". Lausanne....
• [8] ADC Therapeutics S.A.. (6/29/22). "Press Release: ADC Therapeutics Doses First Patient in Phase 1b Clinical Trial of Zynlonta (loncastuximab tesirine-lpyl) in Combination with Other Anti-cancer Agents". Lausanne....
• [9] Ipsen S.A.. (6/27/22). "Press Release: Ipsen to Acquire Epizyme, Expanding Its Portfolio in Oncology". Paris & Cambridge, MA....
• [10] F-Star Therapeutics, Inc.. (6/23/22). "Press Release: invoX Pharma to Acquire F-star Therapeutics, Inc. a Pioneering Next Generation Bispecific Discovery Platform and Clinical Programs". London....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2022. Made in Germany.